INFO & CONTACTS:  +39 02 2390 1

Gemcitabine plus nab-PAclitaxel as switch maiNTEnance versus cONtinuation of modified FOLFIRINOX as first-line chemotherapy in patients with advanced pancreatic cancer: the PANThEON phase III Trial

Phase: Phase III clinical trials

Principal Investigator: Dott. Pietrantonio Filippo

Main Facility: Oncologia Medica Gastroenterologica

Drug: Gemcitabina + Nab-paclitaxel vs mFOLFIRINOX

Pathologies: Intestinal cancer

ClinicalTrials.gov: Read the details about clinical trials

PANThEON is a randomised, open-label, multicentre phase III clinical trial designed to compare maintenance therapy with gemcitabine plus nab-paclitaxel (arm B) versus continuation of treatment with mFOLFIRINOX (arm A) in terms of overall survival (OS) in patients with unresectable LAD or mPDAC who have not experienced disease progression after 3 months of triple induction chemotherapy with mFOLFIRINOX.

The induction chemotherapy regimen will be mFOLFIRINOX, in accordance with the standard of care. Treatment must be continued for a maximum of 14 weeks, corresponding to approximately 6 fortnightly cycles. At least 4 cycles of treatment must have been administered for the patient to be eligible for randomisation.

Radiological assessment of the tumour will be performed before the start and after completion of induction chemotherapy. Patients with a complete/partial response or stable disease (CR/PR/SD) or no evidence of progressive disease (PD) in the case of non-measurable disease will be randomised in a 1:1 ratio between ARM A and ARM B.

Stratification factors will be the ECOG performance status (PS, 0 vs 1) and the extent of the disease (LAD vs metastatic with hepatic metastases vs metastatic without hepatic metastases).

Last update: 16/07/2026

Subscribe to the newsletter

Sign up for our newsletter to stay informed about news, events, and updates from the Institute

Subscribe